Progress of oncolytic viruses in sarcomas

Expert Review of Anticancer Therapy

Volumn 12, Issue 2, 2012, Pages 229-242

  Lettieri, Christina K ^a   Hingorani, Pooja ^a   Kolb, E Anders ^b  

^a PHOENIX CHILDREN'S HOSPITAL   (United States)

^b NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

Author keywords

adenovirus; clinical trial; herpes simplex virus; oncolytic virus; pediatric sarcoma; reovirus; Seneca Valley virus; vesicular stomatitis virus

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CONDITIONALLY REPLICATING ADENOVIRUS; CYCLOPHOSPHAMIDE; FLUOROURACIL; FOLINIC ACID; G 207; GEMCITABINE; H 101; HL; HSV 1716; JX 594; LONTUCIREV; NTX 010; NV 1020; NV 1066; ONCOLYTIC NEWCASTLE DISEASE VIRUS HUJ; ONCOLYTIC SEMLIKI FOREST VIRUS; ONCOLYTIC VESICULAR STOMATITIS VIRUS; ONCOLYTIC VIRUS; PV 701; REOLYSIN; RRP 450; TELOMELYSIN; UNCLASSIFIED DRUG; VINCRISTINE;

ANEMIA; AVIADENOVIRUS; CANCER INHIBITION; CHILDHOOD CANCER; CHONDROSARCOMA; CLINICAL TRIAL (TOPIC); COLORECTAL CARCINOMA; DRUG CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG TOLERABILITY; EWING SARCOMA; FIBROSARCOMA; FLU LIKE SYNDROME; GENETIC ENGINEERING; GLIOBLASTOMA; HEAD AND NECK CANCER; HERPES VIRUS; HUMAN; IMMUNE RESPONSE; LEIOMYOSARCOMA; LIPOSARCOMA; LIVER CELL CARCINOMA; LUNG CANCER; LUNG SMALL CELL CANCER; MALIGNANT FIBROUS HISTIOCYTOMA; MELANOMA; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; NEPHROBLASTOMA; NERVE SHEATH TUMOR; NEUROBLASTOMA; NEUROENDOCRINE TUMOR; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; ONCOLYTIC VIROTHERAPY; OSTEOSARCOMA; OVARY CANCER; PANCREAS CANCER; PICORNAVIRUS; REOVIRUS; RETINOBLASTOMA; REVIEW; RHABDOID TUMOR; RHABDOMYOSARCOMA; SARCOMA; SEMLIKI FOREST ALPHAVIRUS; SENECA VALLEY VIRUS; SINGLE DRUG DOSE; SOFT TISSUE SARCOMA; SOLID TUMOR; SYNOVIAL SARCOMA; TUMOR CELL DESTRUCTION; VACCINIA VIRUS; VESICULAR STOMATITIS VIRUS; VIRUS GENE;

ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; SARCOMA;

EID: 84856841169     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.205     Document Type: Review

References (155)

1. Dock G. The influence of complicating diseases upon leukaemia. Am. J. Med. Sci. 127, 561-592 (1904).
2. Bluming AZ, Ziegler JL. Regression of Burkitts lymphoma in association with measles infection. Lancet 2(7715), 105-106 (1971).
3. Hammill A, Conner J, Cripe T. Oncolytic virotherapy reaches adolescence, review. Pediatr. Blood Cancer 55, 1253-1263 (2010).
4. Kelly E, Russell SJ. History of oncolytic viruses: Genesis to genetic engineering. Mol. Ther. 15, 651-659 (2007). (Pubitemid 46431984)
5. Coukos G, Makrigiannakis A, Kang EHet al. Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer. Clin. Cancer Res. 6, 3342-3353 (2000). (Pubitemid 30637766)
6. Hermiston T. Gene delivery from replication-selective viruses: Arming guided missiles in the war against cancer. J. Clin. Invest. 105(9), 1169-1172 (2000). (Pubitemid 30266066)
7. Prestwich RJ, Errington F, Ilett EJ et al. Tumor infection by oncolytic reovirus primes adaptive antitumor immunity. Clin. Cancer Res. 14 (22), 7358-7366 (2008).
8. Ino Y, Saeki Y, Fukuhara H, Todo T. Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacy. Clin. Cancer Res. 12 (2), 643-652 (2006). (Pubitemid 43166160)
9. Li H, Dutuor A, Tao L, Fu X, Zhang X. Virotherapy with a type 2 herpes simplex virus-derived oncolytic virus induces potent antitumor immunity against neuroblastoma. Clin. Cancer Res. 13(1), 316-322 (2007). (Pubitemid 46121885)
10. Benencia F, Courreges MC, FRaser NW, Coukos G. Herpes virus oncolytic therapy reverses tumor immune dysfunction and facilitates tumor antigen presentation. Cancer Biol. Therapy 7(8), 1194-1205 (2008).
11. Parato KA, Senger D, Forsyth PAJ, Bell JC. Recent progress in the battle between oncolytic viruses and tumours. Nat. Rev. Cancer 5, 965-976 (2005). . Recent excellent review of oncolytic viruses, mechanisms, development of clinical trials, and anti-tumor mechanisms. (Pubitemid 41766784)
12. CHECK Wexler LH, Meyer WH, Helmen LJ et al. Rhabdomyosarcoma the nonrhabdomyosarcoma soft tissue sarcomas. Ewing sarcoma. Osteosarcoma: Biology, diagnosis, treatment, and remaining challenges. In:Principles and Practice of Pediatric Oncology (6th Edition) Pizzo PA, Poplack DG (Eds). Wolters Kluwer/Lippincott Williams & Wilkins Publications, PA, USA, 923-924, 954, 987-988, 1015 (2011).
13. Spunt SL, Skapek SX, Coffin CM. Pediatric nonrhabdomyosarcoma soft tissue sarcomas. Oncologist 13(6), 668-678 (2008). (Pubitemid 351904911)
14. Chao J, Chow WA, Somlo G. Novel targeted therapies in the treatment of soft-tissue sarcomas. Expert Rev. Anticancer Ther. 10(8), 1303-1311 (2010).
15. Hingorani P, Kolb E. Past, present, and future of therapies in pediatric sarcomas. Future Oncol. 6(4), 605-618 (2010).
16. Bharatan NS, Currier MA, Cripe TP. Differential susceptibility of pediatric sarcoma cells to oncolysis by conditionally replication-competent herpes simplex viruses. J. Pediatr. Hematol. Oncol. 24(6), 447-453 (2002).
17. Edelstein ML, Abedi MR, Wixon, J. Gene therapy clinical trials worldwide to 2007 - an update. J. Gene Med. 9, 833-842 (2007). (Pubitemid 47543250)
18. Ganly I, Kirn D, Eckhardt G et al. A Phase I study of ONYX-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin. Cancer Res. 6, 798-806 (2000). (Pubitemid 30159332)
19. Crompton AM, Kirn DH. From ONYX-015 to armed vaccinia viruses: The education and evolution of oncolytic virus development. Curr. Cancer Drug Targets 7, 133-139 (2007). (Pubitemid 46348627)
20. Van Dyke TA. Analysis of viral-host protein interactions and tumorigenesis in transgenic mice. Semin. Cancer Biol. 5, 47-60 (1994). (Pubitemid 124006635)
21. Pesonen S, Kangasniemi L, Hemminki A. Oncolytic adenoviruses for the treatment of human cancer: Focus on translational and clinical data. Mol. Pharm. 8(1), 12-28 (2010). . Nice review of transcription targets and immunologic response in adenoviral oncolysis.
22. Hitt M, Addison C, Graham F. Human adenovirus vectors for gene transfer into mammalian cells. Adv. Pharmacol. 40, 137-206 (1997).
23. Kim NW, Piatyszek MA, Prowse KR et al. Specific association of human telomerase activity with immortal cells and cancer. Science 266, 2011-2015 (1994).
24. Li G, Kawashima H, Ogose A et al. Efficient virotherapy for osteosarcoma by telomerase-specific oncolytic adenovirus. J. Cancer Res. Clin. Oncol. 137, 1037-1051 (2011).
25. Sasaki T, Tazawa H, Hasei J et al. Preclinical evaluation of telomerase-specific oncolytic virotherapy for human bone and soft tissue sarcomas. Clin. Cancer Res. 17(7), 1828-1838 (2011).
26. Nemunaitis J, Tong AW, Nemunaitis M et al. A Phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors. Mol. Ther. 18(2), 429-434 (2010).
27. Nemunaitis J, Ganly I, Khuri F et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, and E1B-55kd gene deleted adenovirus, in patients with advanced head and neck cancer: A Phase II trial. Cancer Res. 60, 6359-6366 (2000).
28. Heise C, Sampson-Johannes A, Williams A, McCormick F, von Hoff DD, Kirn DH. ONYX-015, as E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med. 3, 639-645 (1997). (Pubitemid 27264973)
29. Yu W, Fang H. Clinical trials with oncolytic adenovirus in China. Curr. Cancer Drug Targets 7, 141-148 (2007). (Pubitemid 46348628)
30. Khuri F, Nemunaitis J, Ganly I et al. A controlled trial of ONYX-015, an E1B gene-deleted adenovirus, in combination with chemotherapy in patients with recurrent head and neck cancer. Nat. Med. 6, 879-885 (2000). (Pubitemid 30644745)
31. Reid T, Galanis E, Abbruzzese J et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): Phase II viral, immunologic, and clinical endpoints. Cancer Res. 62, 6070-6079 (2002). (Pubitemid 35244455)
32. Hecht JR, Bedford R, Abbruzzese JL et al. A Phase I/II trial of intratumoral endoscopic ultRasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin. Cancer Res. 9, 555-561 (2003). (Pubitemid 36182584)
33. Vasey PA, Shulman LN, Campos S. Phase I trial of intraperitoneal injection of the E1B-55 kD-gene deleted adenovirus ONYX-015 given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J. Clin. Oncol. 20, 1562-1569 (2002). (Pubitemid 34260536)
34. Nemunaitis J, Cunningham C, Buchanon A et al. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: Safety, feasibility, and biologic activity. Gene Ther. 8, 749-759 (2001).
35. Hamid O, Varteresian M, Wadler S et al. Phase II trial of intravenous C1-1042 in patients with metastatic colorectal cancer. J. Clin. Oncol. 21, 1498-1504 (2003). (Pubitemid 46594102)
36. Kirn D. Clinical research results with dl1520 (Onyx -015), a replication-selective adenvirus for the treatment of cancer: What have we learned? Gene Ther. 8, 89-98 (2001). (Pubitemid 32162422)
37. Fisher KD, Stallwood Y, Green NK, Ulbrich K, Mautner V, Seymour LW. Polymer-coated adenovirus permits efficient retargeting and evades neutralizing antibodies. Gene Ther. 8, 341-348 (2001). (Pubitemid 32241933)
38. Quintanar-Guerrero D, Ganem-Quintanar A, Nava-Arzaluz MG, Pinon-Segundo E. Silica xerogels as pharmaceutical drug carriers. Expert Opin. Drug Delivery 6, 485-498 (2009).
39. ToMKo P, Xu R, Philipson L. The human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc. Natl Acad. Sci. 94, 3352-3356 (1997). (Pubitemid 27157315)
40. Cripe TP, Holub A, Saini A et al. Lack of the adenovirus major attachment receptor limits oncolysis of human rhabdomyosarcoma cells by adenovirus. Proc. Am. Assoc. Can. Res. 41, 452 (2000).
41. Douglas JT, Kim M, Sumerel LA, Carey DE, Curiel DT. Efficient oncolysis by a replicating adenovirus (Ad) in vivo is critically dependent on tumor expression of primary Ad receptors. Cancer Res. 61, 813-817 (2001). (Pubitemid 32174383)
42. Yamamoto M. Curiel DT. Current issues and future directions of oncolytic adenoviruses. Mol. Ther. 18(2), 243-250 (2010).
43. Cripe TP, Dunphy EJ, Holub AD et al. Fiber knob modifications overcome low, heterogeneous expression of the coxsackievirus-adenovirus receptor that limits adenovirus gene transfer and oncolysis for human rhabdomyosarcoma cells. Cancer Res. 61, 2953-2960 (2001). (Pubitemid 32691940)
44. Miller C Buchsbaum D, Reynolds P et al. Differential susceptibility of primary and established human glioma cells to adenovirus infection: Targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Res. 58, 5738-5748 (1998). (Pubitemid 29006415)
45. Korn T, Nettelback DM, Volkel T, Muller R, Kontermann RE. Recombinant bispecific antibodies for the targeting of adenoviruses to CEA-expressing tumor cells: A comparative analysis of bacterially expressed single-chain diabody and tandem scFv. J. Gene Med. 6, 642-651 (2004). (Pubitemid 40228080)
46. Graat HCA, van Beusechem VW, Schagen FHE et al. Intravenous administration of the conditionally replicative adenovirus Ad5-delta 24RGD induces regression of osteosarcoma lung metastases. Mol. Cancer 7, 9 (2008).
47. Hung J, Anderson R. p53: Functions, mutations and sarcomas. Acta Orthop. Scand. 273, 68-73 (1997). (Pubitemid 27085217)
48. Seki A, Kodama J, Miyagi Y, Kamimura S, Yoshinouchi M, Kudo T. Amplification of the mdm-2 gene and p53 abnormalities in uterine sarcomas. Int. J. Cancer 73, 33-37 (1997). (Pubitemid 27445987)
49. Yin L, Liu CX, Nong WX et al. Mutational analysis of p53 and PTEN in soft tissue sarcoma. Mol. Med. Report 5(2), 456-461 5(2), 457-461 (2012).
50. Rice A, Currier MA, Adams LC et al. Ewing sarcoma family of tumors express adenovirus receptors and are susceptible to adenovirus-mediated oncolysis. J. Pediatr. Hematol. Oncol. 24(7), 527-533 (2002). (Pubitemid 36004538)
51. Hoffman D, Heim A, Nettelbeck DM, Steinstraesser L, Wildner O. Evaluation of twenty human adenoviral types and one infectivity-enhanced adenovirus for the therapy of soft tissue sarcoma. Human Gene Ther. 18, 51-62 (2007). (Pubitemid 46105464)
52. Nakagawara A, Milbrandt J, Muramatsu T et al. Differential expression of pleiotrophin and midkine in advanced neuroblastomas. Cancer Res. 55, 1792-1795 (1995).
53. Adachi Y, Reynolds PN, Yamamoto M et al. Midkine promoter-based adenoviral vector gene delivery for pediatric solid tumors. Cancer Res. 60, 4305-4310 (2000). (Pubitemid 32103599)
54. Adachi Y, Reynolds PN, Yamamoto M et al. A midkine promoter-based conditionally replicative adenovirus for treatment of pediatric solid tumors and bone marrow tumor purging. Cancer Res. 61, 882-7888 (2001).
55. Opyrchal M, Aderca I, Galanis E. Phase I clinical trial of locoregional administration of the oncolytic adenovirus ONYX-015 in combination with mitomycin-C, doxorubicin, and cisplatin chemotherapy in patients with advanced sarcomas. In:Methods in Molecular Biology, Gene Therapy of Cancer (Volume 542) Walther W, Stein US (Eds). Humana Press, NY, USA, 705-717 (2009).
56. Galanis E, Okuno SH, Nascimento AG et al. Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. Gene Ther. 12, 437-445 (2005). (Pubitemid 40394296)
57. Hannay J, Davis JJ, Yu D et al. Isolated limb perfusion: A novel delivery system for wild-type p53 and fiber-modified oncolytic adenoviruses to extremity sarcoma. Gene Ther. 14(8), 671-681 (2007). (Pubitemid 46585627)
58. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252, 854-856 (1991). (Pubitemid 121000529)
59. Markert JM, Parker JN, Gillespie GY, Whitley RJ. Genetically engineered human herpes simplex virus in the treatment of brain tumors. Herpes 8, 17-22 (2001). (Pubitemid 32290374)
60. Friedman G, Pressey JG, Reddy A, Markert JM, Gillespie GY. Herpes simplex virus oncolytic therapy for pediatric malignancies. Mol. Ther. 17(7), 1125-1135 (2009).
61. Coffee M, Strong JE, Forsyth PA, Lee, PWK. Reovirus therapy of tumors with activated Ras pathway. Science 282, 1332-1334 (1998). (Pubitemid 28524498)
62. Varghese S, Newsome JT, Rabkin SD et al. Preclinical safety evaluation of G207, a replication-competent herpes simplex virus type 1, inoculated intraprostatically in mice and nonhuman primates. Hum. Gene Ther. 12, 999-1010 (2001). (Pubitemid 32681862)
63. Varghese S, Rabkin SD. Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther. 9, 967-978 (2002). (Pubitemid 35462560)
64. Cinatl J Jr, Cinatl J, Martin M et al. Potent oncolytic activity of multimutated herpes simplex virus G207 in combination with vincristine against human rhabdomyosarcoma. Cancer Res. 63, 1508-1514 (2003). (Pubitemid 36373636)
65. Currier MA, Adams LC, Mahller YY, Cripe TP. Widespread intratumoral virus distribution with fractionated injection enables local control of large human rhabdomyosarcoma xenografts by oncolytic herpes simplex viruses. Cancer Gene Ther. 12, 407-416 (2005). (Pubitemid 40411200)
66. Sugiura S, Goshima F, Takakuwa H, Tetsutaro A, Tsutomu N, Nishiyama Y. Treatment of solid sarcomas in immunocompetent mice with novel, oncolytic herpes simplex virus. Otolaryngol. Head Neck Surgery 130(4), 470-478 (2004). (Pubitemid 38509540)
67. Lan P, Dong C, Qi Y, Xiao G, Xue R. Gene therapy for mice sarcoma with oncolytic herpes simplex virus-1 lacking the apoptosis-inhibiting gene icp34.5. J. Biochem. Mol. Biol. 36(4), 379-389 (2003).
68. Yamamura H, Hashio M, Noguchi, M et al. Identification of the transcriptional regulatory sequences of human calponin promoter and their use in targeting a conditionally replicating herpes vector to malignant human soft tissue and bone tumors. Cancer Res. 61, 3969-3977 (2001). (Pubitemid 32720959)
69. Evans DGR, Baser ME, McGaughran J et al. Malignant peripheral nerve sheath tumours in neurofibromatosis-1. J. Med. Genet. 39, 311-314 (2002). (Pubitemid 34526349)
70. Maldonado AR, Klanke C, Jegga AG et al. Molecular engineering and validation of an oncolytic herpes simplex virus type 1 transcriptionally targeted to midkine-positive tumors. J. Gene Med. 12, 613-623 (2010).
71. Kaur B, Cripe TP, Chiocca EA. 'Buy one get one free': Armed viruses for the treatment of cancer cells and their microenvironment. Curr. Gene Ther. 9(5), 341-355 (2009). .. Excellent review of advances in conditionally-replicative oncolytic virus engineering.
72. Mahller YY, Vaikunth SS, Ripberger MC et al. Tissue inhibitor of metalloproteinase-3 via oncolytic herpesvirus inhibits tumor growth and vascular progenitors. Cancer Res. 68(4), 1161-1168 (2008). . Novel discovery of antiangiogenesis effects of an oncolytic virus on endothelial cell progenitors.
73. Benencia F, Courreges MC, Conejo-Garcia JR et al. Oncolytic HSV exerts direct antiangiogenic activity in ovarian carcinoma. Hum. Gene Ther. 16, 765-778 (2005). (Pubitemid 40864276)
74. Mahller YY, Vaikunth SS, Currier MA et al. Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model. Mol. Ther. 15, 279-286 (2007). (Pubitemid 46111877)
75. Eshun FK, Currier MA, Gillespie RA, Fitzpatrick JL, Baird WH, Cripe TP. VEGF blockade decreases tumor uptake of systemic oncolytic herpes virus but enhances therapeutic efficacy when given after virotherapy. Gene Ther. 17 (7), 922-929 (2010).
76. Chase M, Chung RY, Chiocca EA. An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nat. Biotechnol. 16, 444-448 (1998). (Pubitemid 28211196)
77. Currier MA, Gillespie RA, Sawtell MHet al. Efficacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophosphamide. Mol. Ther. 16(5), 879-885 (2008). (Pubitemid 351587097)
78. Puhlman M, Brown CK, Gnant M et al. Vaccinia as a vector for tumor-directed gene therapy: Biodistribution of a thymidine kinase-deleted mutant. Cancer Gene Ther. 7(1), 66-73 (2000). (Pubitemid 30080989)
79. Merrick AE, Ilett EJ, Melcher AA. JX-594, a targeted oncolytic poxvirus for the treatment of cancer. Curr. Opin. Investig. Drugs 10(12), 1372-1382 (2009).
80. Sakakibara M, Koizumi M, Saikawa Y et al. Membrane-type matrix metalloproteinase-1 expression and activation of gelatinase A as prognostic markers in advanced pediatric neuroblastoma. Cancer 85, 231-239 (1999). (Pubitemid 29031379)
81. Mashour GA, Ratner N, Khan GA, Wang HL, Martuza RL, Kurtz A. The angiogenic factor midkine is aberrantly expressed in NF1-deficient Schwann cells and is a mitogen for neurofibroma-derived cells. Oncogene 20, 97-105 (2001). (Pubitemid 32142342)
82. Liu TC, Zhang T, Fukuhara Het al. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors. Clin. Cancer Res. 12 (22), 6791-6799 (2006). (Pubitemid 44876849)
83. Kanai R, Wakimoto H, Cheema T, Rabkin SD. Oncolytic herpes simplex virus vectors and chemotherapy: Are combinatorial strategies more effective for cancer? Future Oncol. 6, 619-634 (2010). . Thorough review of genetically engineered oncolytic herpes simplex virus-1 and combination strategies.
84. Pawlik TM, Nakamura H, Mullen JT et al. Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene. Cancer 95, 1171-1181 (2002). (Pubitemid 34925371)
85. Guse K, Cerullo V, Hemminki A. Oncolytic vaccinia virus for the treatment of cancer. Expert Opin. Biol. Ther. 11 (5), 595-608 (2011). .. Excellent review of vaccinia virus preclinical and clinical data.
86. Tartaglia J, Pincus S, Paoletti E. Poxvirus-based vectors as vaccine candidates. Crit. Rev. Immunol. 10, 13-30 (1990). (Pubitemid 20074273)
87. Thorne SH, Kirn DH. Future directions for the field of oncolytic virotherapy: A perspective on the use of vaccinia virus. Expert Opin. Biol. Ther. 4(8), 1307-1321 (2004). (Pubitemid 39005736)
88. Buller RM, Smith GL, Cremer K et al. Decreased virulence of recombinant vaccinia virus expression in vectors is assoiciated with thymidine kinase-negative phenotype. Nature 317(6040), 813-815 (1985). (Pubitemid 16195408)
89. Gnant MR, Noll LA, Irvine KR et al. Tumor-specific gene delivery using recombinant vaccinia virus in a rabbit model of liver metastases. J. Natl Cancer Inst. 91(20), 1744-1750 (1999). (Pubitemid 29518770)
90. De Magalhaes JC, Andrade AA, Silva PN et al. A mitogenic signal triggered at an early stage of vaccinia virus infection: Implication of MEK/ERK and protein kinase A in virus multiplication. J. Biol. Chem. 276(42), 38353-38360 (2001).
91. Thorne SH, Hwang TH, O'Gorman WE et al. Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. J. Clin. Invest. 117(11), 3350-3358 (2007). (Pubitemid 350096991)
92. Hwang TH, Moon A, Burke J et al. A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma. Mol. Ther. 19(10), 1913-1922 (2011).
93. Park BH, Hwang T, Liu TC et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: A Phase I trial. Lancet Oncol. 9(6), 533-542 (2008).
94. Breitbach CJ, Burke JB, Jonker D. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 477(7392), 99-102 (2011).
95. Kirn DH, Wang Y, Liang W, Contag CG, Thorne SH. Enhancing poxvirus oncolytic effects through increased spread and immune evasion. Cancer Res. 68, 2071-2075 (2008). (Pubitemid 351521777)
96. Rosen L, Evans HE, Spickard A. Reovirus infections in human volunteers. Am. J. Hyg. 77, 29-37 (1963).
97. Hashiro G, Loh PC, Yau JT. The preferential cytotoxicity of reovirus for certain transformed cell lines. Arch. Virol. 54(4), 307-315 (1977). (Pubitemid 8167247)
98. Thirukkumaran C, Morris DG. Oncolytic viral therapy using reovirus. Methods Mol. Biol. 542, 607-634 (2009).
99. Strong JE, Coffey MC, Tang E, Sabinin P, Lee PWK. The molecular basis of viral oncolysis: Usurpation of the Ras signaling pathway by reovirus. EMBO J. 17(12), 3351-3362 (1998). (Pubitemid 28279509)
100. Bos JL. Ras oncogenes in human cancer: A review. Cancer Res. 49, 4682-4689 (1989). (Pubitemid 19213607)
101. Norman KL, HiRasawa K, Yang ED, Shields MA, Lee PW. Reovirus oncolysis: The Ras/RalGET/p38 pathway dictates host cell permissiveness to reovirus infection. Proc. Natl Acad. Sci. USA 101, 11099-11104 (2004). (Pubitemid 38989590)
102. Harris D, Melcher A, Newbold K et al. A Phase I study to evaluate the feasibility, safety, and biological effects of intratumoural administration of wild type reovirus (Reolysin) in combination with radiation in patients with advanced malignances. Presented at: Annual Meeting of the American Association of Cancer Research. Los Angeles, CA, USA, 14-18 April 2007.
103. Morris D, Forsyth P, Paterson A. A Phase I clinical trial evaluating intralesional reolysin (reovirus) in histologically confirmed malignancies. Proc. Am. Soc. Clin. Oncol. 24a, 92 (2002).
104. Vidal L, Pandha HS, Yap TA et al. A Phase I study of intravenous oncolytic reovirus type 3 dearing in patients with advanced cancer. Clin. Cancer Res. 14(21), 7127-7137 (2008).
105. Gollamudi R, Ghalib M, Desai K et al. Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors. Invest. New Drugs 28, 641-649 (2010).
106. Qiao J, Wang H, Kottke T et al. Cyclophosphamide facilitates anti-tumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. Clin. Cancer Res. 14, 259-269 (2008). (Pubitemid 351378003)
107. Twigger K, Vidal L, White CL et al. Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy. Clin. Cancer Res. 14(3), 912-923 (2008). (Pubitemid 351231176)
108. Karapanagiotou E, Pandha HS, Hall G et al. Phase I Trial of oncolytic reovirus (Reolysin) in combination with carboplatin/paclitaxel in patients with advanced solid cancers. Presented at: International Society for Biological Therapy of Cancer 23rd Annual Meeting. San Diego, CA, USA, 29 October-2 November 2008.
109. Comins C, Spicer J, Portheroe A et al. A Phase I study to evaluate systemic wild-type reovirus (Reolysin) in combination with docetaxel in patients with advanced malignancies. Presented at: International Society for Biological Therapy of Cancer 23rd Annual Meeting. San Diego, CA, USA, 29 October-2 November 2008.
110. Zhang WE, Kolb EA. Reolysin, an unmodified reovirus, has significant anti-tumor activity in childhood sarcomas. Presented at: American Association of Cancer Resistance Meeting. Washington, DC, USA, 1-5 April 2006.
111. Hingorani P, Zhang W, Lin J, Liu L, Chandan G, Kolb EA. Systemic Administration of reovirus (Reolysin) inhibits growth of human sarcoma xenografts. Cancer 117(8), 1764-1774 (2011).
112. Mita AC, Sankhala K, Sarantopoulos J et al. A Phase II study of intravenous REOLYSIN (wild-type reovirus) in the treatment of patients with bone and soft tissue sarcomas metastatic to the lung. Presented at: 15th Annual Connective Tissue Oncology Society Meeting. Miami Beach, FL, USA, 5-7 November 2009.
113. Wadhwa L, Hurwitz MY, Cheves-Barrios, P, Hurwitz RL. Treatment of invasive retinoblastoma in a murine model using an oncolytic picornavirus. Cancer Res. 67, 10653-10656 (2007). (Pubitemid 350145889)
114. Morton CL, Houghton PJ, Kolb EA et al. Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program. Pediatr. Blood Cancer 55, 295-303 (2010).
115. Reddy PS, Burroughs KD, Hales LM et al. Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers. JNCI 99(21), 1623-1633 (2007). .. First to describe the development and remarkable successful oncolysis of Seneca Valley virus-001.
116. Bahrami A, Gowen AM, Baird GS et al. Aberrant expression of epithelial and neuroendocrine markers in alveolar rhabodmyosarcoma: A potentially serious diagnostic pitfall. Mod. Pathol. 21, 795-806 (2008). (Pubitemid 351896668)
117. Lae M, Ahn EH, Mercado GE et al. Global gene expression profiling of PAX-FKHR fusion positive alveolar and PAX-FKHR fusion negative embryonal rhabdomyosarcoma. J. Pathol. 212, 143-151 (2007). (Pubitemid 46852092)
118. Rudin CM, Senzer N, Senzer N, Stephenson J. Phase I study of intravenous Seneca Valley virus (NTX-010), a replication competent oncolytic virus, in patients with neuroendocrine (NE) cancers. J. Clin. Oncol. 27(15S) 4629 (2009).
119. Alexander DJ. Newcastle disease and other avian paramyxoviridae infection. In:Diseases of Poultry (10th Edition) Calnek BW (Ed.). Iowa State University Press, IA, USA, 541-569 (1997).
120. Alexander DJ. Newcastle disease and other avian paramyxoviruses. Rev. Sci. Tech. 9, 443-462 (2000).
121. Stone-Hulslander J, Morrison TG. Detection of an interaction between the HN and F proteins in Newcastle disease virus-infected cells. J. Virol. 71, 6287-6295 (1997). (Pubitemid 27355281)
122. Reichard KW, Lorence RM, Cascino CJ. Newcastle disease virus selectively kills human tumor cells. J. Surg. Res. 52, 448-453 (1992).
123. Ravindra PV, Tiwari AK, Sharma B, Chauhan RS. Newcastle disease virus as an oncolytic agent. Indian J. Med. Res. 130(5), 507-513 (2009).
124. Stodjl DF, Lichty B, Knowles S et al. Exploiting tumors-pecific defects in the interferon pathway with a previously unknown oncolytic virus. Nat. Med. 6, 821-825 (2000). (Pubitemid 30469434)
125. Elankumaran S, Chavan V, Qiao D et al. Type I interferon-sensitive recombinant Newcastle disease virus for oncolytic virotherapy. J. Virol. 84(8), 3835-3844 (2010).
126. Pecora AL, Rizvi N, Cohen GI et al. Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J. Clin. Oncol. 20, 2251-2266 (2002). (Pubitemid 34441652)
127. Lorence RM, Pecora AL, Major PP et al. Overview of Phase I studies of intravenous administration of PV701, an oncolytic virus. Curr. Opin. Mol. Ther. 5, 618-624 (2003). (Pubitemid 38094433)
128. Vigil A, Park MS, Martinez O et al. Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus. Cancer Res. 67(17), 8285-8292 (2007). (Pubitemid 47395166)
129. Nakamura T, Russell SJ. Oncolytic measles virus for cancer therapy. Expert Opin. 4(10), 1685-1692 (2004). (Pubitemid 39371764)
130. Ketola A, Hinkkanen A, Yongabi F et al. Oncolytic semliki forest virus vector as a novel candidate against unresectable osteosarcoma. Cancer Res. 68, 8342-8350 (2008).
131. Porosnicu M, Mian A, Barber GN. The oncolytic effect of recombinant vesicular stomatitis virus is enhanced by expression of the fusion cytosine deaminase/uracil phosphoribosyl transferase suicide gene. Cancer Res. 63(23), 8366-8378 (2003).
132. Barrett PN, Sheahan BJ, Atkins GJ. Isolation and preliminary characterization of Semliki Forest virus mutants with altered virulence. J. Gen. Virol. 49, 141-147 (1980). (Pubitemid 10015411)
133. Wagner RR, Rose JK. Rhabdoviridae: The viruses and their replication. In:Fields Virology (3rd Edition). Fields BN, Knipe DM, Howley PM et al. (Eds). Lippincott-Raven Publishers, PA, USA, 1121-1135 (1996).
134. Paglino JC, van den Pol AN. Vesicular stomatitis virus has extensive oncolytic activity against human sarcomas: Rare resistance is overcome by blocking interferon pathways. J. Virol. 85(18), 9346-9358 (2011).
135. Wu Y, Lun X, Zhou Het al. Oncolytic Efficacy of recombinant vesicular stomatitis virus and myxoma virus in experimental models of rhabdoid tumors. Clin. Cancer Res. 14(4), 1218-1227 (2008). (Pubitemid 351302571)
136. Kubo, T, Shimose S, Matsuo T et al. Oncolytic vesicular stomatitis virus administered by isolated limb perfusion suppresses osteosarcoma growth. J. Orthop. Res. 29(5), 795-800 (2011).
137. Breitback CJ, Paterson JM, Lemay CG et al. Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol. Ther. 15, 1686-1693 (2007). (Pubitemid 47289013)
138. Kirn DH, Wang Y, Le Boeuf F, Bell J, Thorne SH. Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus. PLoS Med. 4, e353 (2007).
139. Breitback CJ, Silva NS, Falls T. Targeting tumor vasculature with an oncolytic virus. Mol. Ther. 19(5), 886-894 (2011).
140. Fulci G, Breymann L, Gianni D et al. Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc. Natl Acad. Sci. USA 103, 12873-12876 (2006).
141. Li J, O'Malley M, Urban J. Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer. Mol. Ther. 19(4), 650-657 (2011).
142. Mastrangelo MJ, Maguire HC Jr, Eisenlohr LC et al. Intratumoral recombinant GM-CSF encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther. 6(5), 409-422 (1999). (Pubitemid 129667814)
143. Cerullo V, Pesonen S, Diaconu I et al. Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res. 70(11), 4259-4309 (2010).
144. Liu BL, Robinson M, Han ZQ et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumor properties. Gene Ther. 10(4), 292-303 (2003). (Pubitemid 36305598)
145. Willmon C, Harrington K, Kottke T, Prestwich R, Melcher A, Vile R. Cell carriers for oncolytic viruses: Fed Ex for cancer therapy. Mol. Ther. 17(10), 1667-1676 (2009).
146. Verneris MR, Karami M, Baker J, Jayaswal A. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood 103(8), 3065-3072 (2004). (Pubitemid 38451682)
147. Thorne SH, Negrin RS, Contag CH. Synergistic antitumor effects of immune cell-viral biotherapy. Science 311, 1780-1784 (2006).
148. Thorne SH, Liang W, Sampath P et al. Targeting localized immune suppression within the tumor through repeat cycles of immune cell-oncolytic virus combination therapy. Mol. Ther. 18(9), 1698-1705 (2010).
149. Thorne S. Immunotherapeutic potential of oncolytic vaccinia virus. Immunol. Res. 50, 286-293 (2011). .. Exciting description of recent success in combining oncolytic vaccinia with immune cell therapies.
150. Hoster H, Zanes R, von Haam E. The association of 'viral' hepatitis and Hodkin's disease. Cancer Res. 9, 473-480 (1949).
151. Jordan, CT. Cancer stem cells: Controversial or just misunderstood? Cell Stem Cell 4, 203-205 (2009).
152. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 414, 105-111 (2001). (Pubitemid 33041634)
153. Cripe TP, Wang PY, Marcato P, Mahller YY, Lee PWK. Targeting cancer-initiating cells with oncolytic viruses. Mol. Ther. 17(10), 1677-1682 (2009).
154. Mahller YY, Williams JP, Baird WHet al. Neuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virus. PLoS One 4(1), e4235 (2009).
155. Spyra M, Kluwe L, Hagel C et al. Cancer stem cell-like cells derived from malignant peripheral nerve sheat tumors. PLoS One 6(6), e21099 (2011).